Lifeboat Foundation

Neurological conditions or injuries that result in the inability to communicate can be devastating. Patients with such speech loss often rely on alternative communication devices that use brain–computer interfaces (BCIs) or nonverbal head or eye movements to control a cursor to spell out words. While these systems can enhance quality-of-life, they can only produce around 5–10 words per minute, far slower than the natural rate of human speech.

Researchers from the University of California San Francisco today published details of a neural decoder that can transform brain activity into intelligible synthesized speech at the rate of a fluent speaker (Nature 10.1038/s41586-019‑1119-1).

“It has been a longstanding goal of our lab to create technology to restore communication for patients with severe speech disabilities,” explains neurosurgeon Edward Chang. “We want to create technologies that can generate synthesized speech directly from human brain activity. This study provides a proof-of-principle that this is possible.”

Strong winds and high temperatures are expected to bring flames to more populated areas, including the suburbs of Sydney.

Your perspective is always limited by how much you know. Expand your knowledge and you will transform your mind. ~ Dr. Bruce Lipton.

A 3D-Bioplotter® was employed to 3D print (3DP) a humic acid-polyquaternium 10 (HA-PQ10) controlled release fixed dose combination (FDC) tablet comprising of the anti-HIV-1 drugs, efavirenz (EFV), tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC).

Chemical interactions, surface morphology and mechanical strength of the FDC were ascertained. In vitro drug release studies were conducted in biorelevant media followed by in vivo study in the large white pigs, in comparison with a market formulation, Atripla®. In vitro-in vivo correlation of results was undertaken.

EFV, TDF and FTC were successfully entrapped in the 24-layered rectangular prism-shaped 3DP FDC with a loading of ∼12.5 mg/6.3 mg/4 mg of EFV/TDF/FTC respectively per printed layer. Hydrogen bonding between the EFV/TDF/FTC and HA-PQ10 was detected which was indicative of possible drug solubility enhancement. The overall surface of the tablet exhibited a fibrilla structure and the 90° inner pattern was determined to be optimal for 3DP of the FDC. In vitro and in vivo d rug release profiles from the 3DP FDC demonstrated that intestinal-targeted and controlled drug release was achieved.

The new technology enables the printing of personalized medications out of hydrogel objects, producing complex structures which can expand, change shape and activate on a delayed schedule. By prescribing personalized medicines, doctors will be able to accurately tailor the exposure and dosage levels for individual patients.

“We now have the technology to replace standard or traditional formulations. The population is getting older so we need to think of solutions,” said Benny.

“We can now think about combining drugs together into one drug instead of ten, to adjust the kinetics of drugs and improve patient compliance in drug administration.”

The findings of a new study suggest that the accumulation of toxic beta-amyloid proteins in the brain may not be the cause of Alzheimer’s disease.

3D printing drugs is driving the pharmaceutical industry towards personalized medicine. Let’s take a look at the most recent trends and developments.

“Finally, Artifical [sic] Intelligence that will make you wonder which one of you is real,” reads one of Kapur’s recent tweets, with another urging CES visitors to stop by the NEON corner to learn more about “an Artificial Intelligence being as your best friend.”

Not Bixby

One thing Samsung will say about NEON is that it is not related to the company’s AI-powered digital assistant Bixby.

The breakthrough system combines a glucose sensor, insulin pump and a smart control algorithm to allow Type 1 diabetes patients to continually regulate blood-sugar levels.